Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMMU
  • CUSIP: 45290710
  • Web: www.immunomedics.com
Capitalization:
  • Market Cap: $978.34 million
  • Outstanding Shares: 109,604,000
Average Prices:
  • 50 Day Moving Avg: $8.39
  • 200 Day Moving Avg: $6.31
  • 52 Week Range: $2.02 - $9.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.59
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.38 million
  • Price / Sales: 279.52
  • Book Value: ($1.20) per share
  • Price / Book: -7.18
Profitability:
  • EBIDTA: ($63,800,000.00)
  • Net Margins: -3,426.56%
  • Return on Assets: -142.88%
Debt:
  • Debt-to-Equity Ratio: -0.74%
  • Current Ratio: 0.57%
  • Quick Ratio: 0.56%
Misc:
  • Average Volume: 2.84 million shs.
  • Beta: 1.73
  • Short Ratio: 7.79
 

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings results on Thursday, February, 9th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03. The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 analysts have issued 12-month price targets for Immunomedics' stock. Their predictions range from $11.00 to $11.00. On average, they expect Immunomedics' stock price to reach $11.00 in the next year. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 33,776,195 shares, an increase of 1.9% from the June 15th total of 33,152,898 shares. Based on an average daily trading volume, of 2,870,961 shares, the short-interest ratio is presently 11.8 days. Currently, 33.6% of the shares of the company are sold short.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Jason M. Aryeh, Chairman of the Board
  • Cynthia L. Sullivan, President, Chief Executive Officer, Director
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
  • Geoffrey F. Cox Ph.D., Independent Director
  • Robert Forrester, Independent Director
  • Brian A. Markison, Lead Independent Director
  • Bob Oliver, Independent Director

Who owns Immunomedics stock?

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include VENBIO SELECT ADVISOR LLC (9.90%), Creative Planning (0.16%) and NEXT Financial Group Inc (0.09%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have sold Immunomedics stock in the last year include Don C Stark and Mary E Paetzold. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $8.62.


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (27.61% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Jefferies Group LLCReiterated RatingBuy$11.00LowView Rating Details
5/26/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
5/5/2017Wells Fargo & CompanyUpgradeMarket Perform -> OutperformHighView Rating Details
7/29/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperformN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Immunomedics (NASDAQ:IMMU)
Earnings by Quarter for Immunomedics (NASDAQ:IMMU)
Earnings History by Quarter for Immunomedics (NASDAQ IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
2017 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 62.06%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Immunomedics (NASDAQ:IMMU)
Latest Headlines for Immunomedics (NASDAQ:IMMU)
Source:
DateHeadline
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:56 AM
americanbankingnews.com logoFY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group
www.americanbankingnews.com - July 17 at 11:11 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU)
www.americanbankingnews.com - July 15 at 4:12 PM
americanbankingnews.com logoJefferies Group Comments on Immunomedics, Inc.'s FY2022 Earnings (IMMU)
www.americanbankingnews.com - July 14 at 3:56 PM
finance.yahoo.com logoPublished Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers
finance.yahoo.com - July 10 at 7:51 PM
finance.yahoo.com logoETFs with exposure to Immunomedics, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 7:51 PM
nasdaq.com logoPre-Market Most Active for Jul 3, 2017 : SIRI, MU, PBR, IMMU, VIPS, BAC, USLV, TSLA, SPIL, RAD, NRG, CHK - Nasdaq
www.nasdaq.com - July 3 at 7:20 PM
streetinsider.com logoForm 8-K IMMUNOMEDICS INC For: Jun 29 - StreetInsider.com
www.streetinsider.com - July 1 at 1:00 AM
nasdaq.com logoImmunomedics Announces Results of Special Stockholder Meeting - Nasdaq
www.nasdaq.com - June 30 at 5:14 AM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Immunomedics (IMMU) Stock
finance.yahoo.com - June 30 at 12:10 AM
finance.yahoo.com logoImmunomedics Announces Results of Special Stockholder Meeting
finance.yahoo.com - June 30 at 12:10 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Short Interest Update
www.americanbankingnews.com - June 28 at 7:14 AM
finance.yahoo.com logoETFs with exposure to Immunomedics, Inc. : June 27, 2017
finance.yahoo.com - June 27 at 6:06 PM
finance.yahoo.com logoETFs with exposure to Immunomedics, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 6:44 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Given a $9.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - June 11 at 10:52 PM
investopedia.com logoThree Junior Biotechs Ready to Run (IMMU, STDY)
www.investopedia.com - June 7 at 5:28 PM
finance.yahoo.com logoETFs with exposure to Immunomedics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 5:56 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - June 4 at 11:14 AM
finance.yahoo.com logoImmunomedics to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 6:44 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Coverage Initiated at Cowen and Company
www.americanbankingnews.com - May 26 at 2:52 PM
finance.yahoo.com logoETFs with exposure to Immunomedics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 2:17 AM
finance.yahoo.com logoImmunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 11:33 AM
rttnews.com logoCompany Spotlight: Immunomedics
www.rttnews.com - May 12 at 6:36 PM
finance.yahoo.com logoEdited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT
finance.yahoo.com - May 12 at 2:04 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Short Interest Up 12.4% in April
www.americanbankingnews.com - May 11 at 7:34 AM
reuters.com logoBRIEF-Immunomedics Q3 loss per share $0.55
www.reuters.com - May 10 at 6:22 PM
finance.yahoo.com logoImmunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoImmunomedics reports 3Q loss
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoImmunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results
finance.yahoo.com - May 10 at 1:20 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Immunomedics, Inc.'s FY2017 Earnings (IMMU)
www.americanbankingnews.com - May 10 at 9:58 AM
americanbankingnews.com logoImmunomedics (IMMU) Earns Daily Coverage Optimism Score of 0.19
www.americanbankingnews.com - May 9 at 12:50 AM
finance.yahoo.com logoImmunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017
finance.yahoo.com - May 8 at 5:33 PM
bizjournals.com logoBiotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics
www.bizjournals.com - May 8 at 7:18 AM
finance.yahoo.com logoImmunomedics Breaks Out, But Will It Last?
finance.yahoo.com - May 8 at 7:18 AM
finance.yahoo.com logoDid Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?
finance.yahoo.com - May 6 at 9:50 AM
americanbankingnews.com logoImmunomedics (IMMU) Receives Daily Media Sentiment Score of 0.22
www.americanbankingnews.com - May 5 at 11:22 PM
reuters.com logoBRIEF-Immunomedics announces private placement offering
www.reuters.com - May 5 at 10:54 PM
finance.yahoo.com logoImmunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value
finance.yahoo.com - May 5 at 10:54 PM
reuters.com logoBRIEF-Immunomedics announces private placement offering - Reuters
www.reuters.com - May 5 at 5:52 PM
fool.com logoWhy Immunomedics, Inc. Rocketed Today - Motley Fool
www.fool.com - May 5 at 5:52 PM
finance.yahoo.com logoWhy Immunomedics, MercadoLibre, and Pearson Jumped Today
finance.yahoo.com - May 5 at 5:52 PM
finance.yahoo.com logoImmunomedics, Seattle Genetics Scrap License Deal
finance.yahoo.com - May 5 at 5:52 PM
fool.com logoWhy Immunomedics, Inc. Rocketed Today
www.fool.com - May 5 at 2:53 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Stock Rating Upgraded by Wells Fargo & Co
www.americanbankingnews.com - May 5 at 12:34 PM
americanbankingnews.com logoImmunomedics (IMMU) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 3 at 12:20 AM
americanbankingnews.com logoImmunomedics (IMMU) Receiving Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 4:44 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Short Interest Down 4.5% in April
www.americanbankingnews.com - April 28 at 7:12 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Impact Immunomedics (IMMU) Stock Price
www.americanbankingnews.com - April 25 at 9:06 PM
finance.yahoo.com logoImmunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : April 25, 2017
finance.yahoo.com - April 25 at 5:22 PM
finance.yahoo.com logoImmunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017
finance.yahoo.com - April 24 at 9:12 AM

Social

Chart

Immunomedics (IMMU) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff